Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829918 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT02829918: Completed Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT02829918 is a Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 54 participants, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02829918, a Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is designed to see if a drug called Nivolumab is effective in treating patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not approved by the FDA for treatment of your type of cancer.
Primary Outcome
Response in participants with advanced biliary tract cancers receiving nivolumab as a single agent. ORR is defined as complete responses (CR) plus partial responses (PR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (3)
California
- City of Hope Cancer Center - Duarte
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
What the finished NCT02829918 record still lists
NCT02829918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Biliary Tract Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT02829918 reports a single indexed study location in California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02829918 about?
NCT02829918 is a clinical study titled "Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers". This research study is designed to see if a drug called Nivolumab is effective in treating patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not approved by the FDA for t...
What is the current status of trial NCT02829918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2016-10-05. Estimated completion is 2023-05-24.
What conditions does trial NCT02829918 study?
This clinical trial studies the following conditions: Biliary Tract Cancer, Biliary Tract Neoplasms.
What interventions are being tested in trial NCT02829918?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02829918?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02829918 being conducted?
This trial has 3 study locations across California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02829918's enrollment target sits among peer trials
54 28th of 36 higher than 9 of 36 other Biliary Tract Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Tract Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI